scispace - formally typeset
E

Elisa Giovannetti

Researcher at VU University Medical Center

Publications -  388
Citations -  17504

Elisa Giovannetti is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 51, co-authored 341 publications receiving 14218 citations. Previous affiliations of Elisa Giovannetti include Fondazione Pisa & VU University Amsterdam.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

Alessandro Leonetti, +6 more
- 29 Oct 2019 - 
TL;DR: The molecular mechanisms of resistance to osimertinib in patients with advanced EGFR-mutated NSCLC, including MET/HER2 amplification, activation of the RAS–mitogen-activated protein kinase (MAPK) or RAS-phosphatidylinositol 3-kinase (PI3K) pathways, novel fusion events and histological/phenotypic transformation are summarized.
Journal ArticleDOI

MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity

Elisa Giovannetti, +13 more
- 01 Jun 2010 - 
TL;DR: Modulation of apoptosis, Akt phosphorylation, and expression of genes involved in invasive behavior may contribute to the role of miR-21 in gemcitabine chemoresistance and to the rational development of new targeted combinations.
Journal ArticleDOI

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

Elisa Giovannetti, +13 more
- 01 Apr 2006 - 
TL;DR: It is suggested that the expression levels of hENT1 may allow the stratification of patients based on their likelihood of survival, thus offering a potential new tool for treatment optimization.
Journal ArticleDOI

Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.

Jin Hyeok Hwang, +17 more
- 14 May 2010 - 
TL;DR: Evidence is provided that miR-21 may allow stratification for adjuvant therapy, and represents a new potential target for therapy in PDAC, as well as the single most predictive biomarker for treatment outcome.